Non-Insulin Therapies for Diabetes Market By Therapy Type (Oral Medications, Injectable Medications), By Drug Class (GLP-1 Receptor Agonists, SGLT-2 Inhibitors, DPP-4 Inhibitors, Thiazolidinediones, Alpha-Glucosidase Inhibitors, Meglitinides), By End-User (Hospitals & Clinics, Home Care), By Route of Administration (Oral, Injectable), By Distribution Channel (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies), and By Region; Global Insights & Forecast (2023 – 2030)

As per Intent Market Research, the Non-Insulin Therapies for Diabetes Market was valued at USD 30.1 Billion in 2024-e and will surpass USD 41.4 Billion by 2030; growing at a CAGR of 5.4% during 2025-2030.

The non-insulin therapies for diabetes market is rapidly expanding as a result of the increasing prevalence of Type 2 diabetes and the growing demand for alternative treatments that do not rely on insulin injections. These therapies are particularly important for managing blood sugar levels in patients with Type 2 diabetes, offering a variety of options including oral medications, injectables, and different drug classes. The market is characterized by dynamic growth across multiple segments, driven by both the advancement of therapeutic options and changing patient preferences. This market’s growth is also supported by innovations in drug delivery systems, improved patient outcomes, and expanding healthcare access in emerging regions.

Therapy Type Segment Is Largest Owing To Oral Medications' Accessibility and Convenience

The non-insulin therapies for diabetes market is witnessing significant growth, driven by the demand for more accessible and effective treatment options for managing diabetes. Among the various therapeutic options available, oral medications have emerged as the largest subsegment due to their widespread acceptance and ease of use. Patients prefer oral medications as they eliminate the need for injections, making them a more convenient option for managing Type 2 diabetes. Additionally, oral medications are often more affordable and accessible compared to injectables, driving their adoption in both developed and emerging markets.

The growing prevalence of Type 2 diabetes, coupled with the increasing shift towards preventative care and early-stage management, makes oral medications a crucial part of diabetes treatment regimens. Medications such as DPP-4 inhibitors and SGLT-2 inhibitors are commonly prescribed in oral form, making them the preferred choice for many patients, especially those newly diagnosed or with mild to moderate diabetes. With their established efficacy and patient-friendly administration, oral medications are expected to maintain their dominance in the market.

Drug Class Segment Is Fastest Growing Owing To GLP-1 Receptor Agonists' High Efficacy

The drug class segment in the non-insulin therapies for diabetes market is experiencing rapid growth, with GLP-1 receptor agonists emerging as the fastest-growing subsegment. These drugs have gained significant attention due to their dual action of enhancing insulin secretion and reducing glucagon release, which helps in lowering blood glucose levels effectively. GLP-1 receptor agonists, such as liraglutide and semaglutide, have shown impressive results in controlling blood sugar levels and promoting weight loss, making them highly sought after in diabetes treatment.

The increased adoption of GLP-1 receptor agonists is also fueled by their potential benefits beyond blood glucose control, including cardiovascular protection, which is particularly important for diabetic patients at risk of heart disease. The growing awareness of these advantages and the launch of new formulations with improved patient compliance are contributing to the rapid expansion of this drug class. As more patients seek effective and holistic diabetes management solutions, GLP-1 receptor agonists are poised to become a cornerstone of Type 2 diabetes therapy.

End-User Segment Is Largest Owing To Hospitals & Clinics' Central Role in Diabetes Care

The end-user segment in the non-insulin therapies for diabetes market is primarily dominated by hospitals and clinics, which play a central role in the diagnosis, treatment, and management of diabetes. Healthcare facilities are equipped with the necessary infrastructure and expert personnel to provide comprehensive care for diabetic patients, making them the largest end-users of non-insulin therapies. Hospitals and clinics also benefit from their ability to prescribe a wide range of therapies, including newer and more specialized non-insulin medications such as GLP-1 receptor agonists and SGLT-2 inhibitors.

The increasing burden of diabetes, both in terms of prevalence and complications, has led to a rise in patient visits to healthcare facilities, further bolstering this subsegment. Additionally, hospitals and clinics are at the forefront of clinical trials for new diabetes therapies, contributing to ongoing advancements in treatment options. As healthcare systems continue to prioritize diabetes management, the hospital and clinic segment will remain a key driver of market growth.

Distribution Channel Segment Is Largest Owing To Retail Pharmacies' Accessibility and Reach

The distribution channel segment in the non-insulin therapies for diabetes market is dominated by retail pharmacies, which provide widespread access to diabetes medications. Retail pharmacies are the most accessible and convenient option for the general population, offering over-the-counter and prescription-based non-insulin therapies. With their widespread presence and ease of access, retail pharmacies are the primary channel for distributing oral and injectable diabetes medications. This accessibility plays a significant role in the adoption of non-insulin therapies across diverse patient populations, from urban centers to rural areas.

Retail pharmacies also benefit from the growing trend of patients seeking more self-managed healthcare options, including refilling prescriptions and consulting pharmacists for guidance on diabetes medications. As a result, retail pharmacies are expected to continue playing a central role in the distribution of diabetes therapies, contributing significantly to the market's growth. The increasing demand for diabetes medications in retail outlets reflects the ongoing shift towards more patient-centric care models.

Geography Segment Is Largest Owing To North America's Advanced Healthcare Infrastructure

Geographically, North America holds the largest share of the non-insulin therapies for diabetes market. The region benefits from advanced healthcare infrastructure, higher healthcare spending, and widespread access to modern diabetes treatments, including non-insulin therapies. With a large diabetic population in the United States and Canada, the demand for effective diabetes medications, especially oral and injectable therapies, is significant. Furthermore, the increasing focus on preventative healthcare and early diabetes management is contributing to market growth in this region.

The presence of leading pharmaceutical companies and research institutions in North America also plays a vital role in driving the development and availability of innovative diabetes treatments. With the continuous introduction of new therapies and treatment options, North America is expected to maintain its dominance in the global non-insulin therapies market. Additionally, initiatives to improve diabetes care, such as reimbursement programs and patient education, are further supporting the growth of the market in this region.

Competitive Landscape: Leading Companies and Market Dynamics

The non-insulin therapies for diabetes market is highly competitive, with several global pharmaceutical companies leading the charge in the development, production, and distribution of diabetes medications. Companies like Novo Nordisk, Eli Lilly, Merck, and AstraZeneca are key players in the market, with a strong portfolio of oral and injectable diabetes therapies. These companies are focusing on expanding their product offerings, conducting clinical trials, and improving patient compliance through innovative drug delivery systems.

The competitive landscape is characterized by ongoing mergers and acquisitions, strategic partnerships, and continuous research and development efforts. As the market evolves, companies are increasingly focusing on personalized medicine and patient-centric solutions to cater to the diverse needs of diabetes patients. With the growing prevalence of diabetes worldwide, the market for non-insulin therapies is expected to remain highly competitive, with players striving to maintain their market share through innovation and strategic initiatives.

Recent Developments:

• Novo Nordisk launched a new GLP-1 receptor agonist, aiming to improve blood sugar control for patients with Type 2 diabetes.
• Eli Lilly received FDA approval for a new oral SGLT-2 inhibitor for Type 2 diabetes management.
• AstraZeneca completed its acquisition of a diabetes-focused biopharmaceutical company to enhance its portfolio of non-insulin therapies.
• Sanofi announced the launch of a next-generation DPP-4 inhibitor designed to improve patient adherence.
• Merck & Co. expanded its diabetes care portfolio with a new injectable therapy to be used alongside existing diabetes medications.

List of Leading Companies:

• Novo Nordisk
• Eli Lilly and Co.
• Merck & Co.
• AstraZeneca
• Sanofi
• Boehringer Ingelheim
• GlaxoSmithKline
• Johnson & Johnson
• Bayer AG
• AbbVie
• Takeda Pharmaceutical Company
• Novartis
• Pfizer
• Roche
• Amgen

Report Scope: